ClinicalTrials.gg
CompletedNCT01986933Updated Jan 25, 2022Results posted

A Phase 2 Study of CIM331 for Atopic Dermatitis Patients

A Phase 2 interventional study of nemolizumab (CIM331) and Placebo in Atopic Dermatitis, sponsored by Chugai Pharmaceutical. Completed at 18 sites in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2022-01-25.

Sponsored by Chugai Pharmaceutical (part of Hoffmann-La Roche) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
264
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 14 studies testing nemolizumab in Dermatitis, Atopic — 3 open to participants now, 3 under way, 1 of them phase 3. nemolizumab · Dermatitis, Atopic.

Enrollment
4th of 14
264 · median 209
Started
2013
the only one that year
Phase 2
7 of 14
1 open now
Registered
1st of 14
by date
Lead sponsor
1 of 14
Chugai Pharmaceutical

Among the 14 studies testing nemolizumab in Dermatitis, Atopic, this one is the 4th largest by enrollment, is the only one that started in 2013, is one of 7 in phase 2, and was the 1st registered.

Dermatitis, Atopic

1,594 studies on the registry are indexed under Dermatitis, Atopic; 287 are open to participants now.

Browse Dermatitis, Atopic studies →

Open to participants now

3 of the 14 studies testing nemolizumab in Dermatitis, Atopic are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About nemolizumab

nemolizumab: first FDA approval 2024 (NEMLUVIO), first EMA approval 2025. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 195 Dermatitis, Atopic studies recruiting now, 83 (43%) set no upper age limit and 96 (49%) stop at 75 or younger; 94 take children under 18; 52 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies testing nemolizumab in Dermatitis, Atopic, or all of them as a file.
02

Study summary

To assess the safety, tolerability and efficacy of CIM331, compared to placebo, in atopic dermatitis patients who are inadequately controlled by or intolerant to topical therapy

03

Conditions studied

  • Atopic Dermatitis

Browse trials for

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • ≥18 and ≤65 years of age at the time of consent.
  • Patients with Atopic Dermatitis
  • Pruritus visual analogue scale (VAS) ≥50 mm at the screening and baseline visit
  • Eczema Area and Severity Index (EASI) ≥10 at the screening and baseline visit
  • static Investigator's Global Assessment (sIGA) score ≥3 at the baseline visit

Exclusion criteria

Exclusion Criteria:

  • Serological evidence of virus or virus infection
  • Known infection
  • Ongoing treatment with specific or non-specific hyposensitization therapy for AD
  • Treatment with mild or moderately potent topical (TCS) within 1 week prior to randomization
  • History of infection including skin infection requiring treatment with oral or intravenous (IV) antibiotics, antivirals, or antifungals within 1 week prior to randomization.
  • Evidence of tuberculosis (TB) infection as defined by a positive purified protein derivative (PPD) and/or positive interferon-gamma release assay.
  • Pregnant or lactating women.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
264 participants (actual)

Study arms

  • Experimental
    Group1

    Part A: nemolizumab (CIM331) Part B: nemolizumab (CIM331)

    Drug: nemolizumab (CIM331)

  • Experimental
    Group2

    Part A: nemolizumab (CIM331) Part B: nemolizumab (CIM331)

    Drug: nemolizumab (CIM331)

  • Experimental
    Group3

    Part A: nemolizumab (CIM331) Part B: nemolizumab (CIM331)

    Drug: nemolizumab (CIM331)

  • Experimental
    Group4

    Part A: nemolizumab (CIM331) Part B: nemolizumab (CIM331)

    Drug: nemolizumab (CIM331)

  • Experimental
    Group5

    Part A: Placebo Part B: nemolizumab (CIM331)

    Drug: nemolizumab (CIM331) · Other: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Percent Changes From Baseline in Pruritus Visual Analogue Scale (VAS) at Week 12

    Percent changes from baseline in pruritus VAS at Week 12. VAS indicates pruritus intensity in the last 24 hours, from 0 (no itch) to 10 (worst imaginable itch). When condition of pruritus improves, percent change from baseline at Week 12 indicates negative value (i.e. the higher the absolute value is, the more the condition improves).

    Time frame: baseline to Week 12

Secondary outcomes

  1. Changes From Baseline in Eczema Area and Severity Index (EASI) (Part A, PP Population)

    EASI score was used to measure the severity and extent of atopic eczema. The intensity of a representative area of eczema and the approximate percentage affected by eczema were calculated for each of the four body regions: head and neck, upper limbs, trunk, and lower limbs. The sum of the above 4 body region scores was calculated and should be 0 (none) to 72 (severest). When the condition of eczema improves, the percent change from baseline at each timepoint indicates negative value (i.e. the higher the absolute value is, the more the condition improves).

    Time frame: baseline to Week 12 (Part A)

  2. Changes From Baseline in Eczema Area and Severity Index (EASI) (Part A + Part B, ITT Long Population)

    EASI score was used to measure the severity and extent of atopic eczema. The intensity of a representative area of eczema and the approximate percentage affected by eczema were calculated for each of the four body regions: head and neck, upper limbs, trunk, and lower limbs. The sum of the above 4 body region scores was calculated and should be 0 (none) to 72 (severest). When the condition of eczema improves, the percent change from baseline at each timepoint indicates negative value (i.e. the higher the absolute value is, the more the condition improves).

    Time frame: baseline to Week 12 (Part A), up to Week 64 (Part B)

  3. Changes From Baseline in SCORing Atopic Dermatitis (SCORAD) (Part A, PP Population)

    SCORAD is a clinical tool used to assess the extent and severity of eczema. Area and intensity, were assessed by the Investigator and subjective symptoms were reported by the patient in order to determine an overall score. The score should be 0 to 103: mild \[\<25\], moderate \[25-50\] or severe \[\>50\]). When the condition of eczema improves, the percent change from baseline at each timepoint indicates negative value (i.e. the higher the absolute value is, the more the condition improves).

    Time frame: baseline to Week 12 (Part A)

  4. Changes From Baseline in SCORing Atopic Dermatitis (SCORAD) (Part A + Part B, ITT Long Population)

    SCORAD is a clinical tool used to assess the extent and severity of eczema. Area and intensity, were assessed by the Investigator and subjective symptoms were reported by the patient in order to determine an overall score. The score should be 0 to 103: mild \[\<25\], moderate \[25-50\] or severe \[\>50\]). When the condition of eczema improves, the percent change from baseline at each timepoint indicates negative value (i.e. the higher the absolute value is, the more the condition improves).

    Time frame: baseline to Week 12 (Part A), up to Week 64 (Part B)

  5. Changes From Baseline in Static Investigator's Global Assessment (sIGA) (Part A, PP Population)

    The sIGA consisted of a 6-point severity scale from clear to very severe disease (0 = clear, 1 = almost clear, 2 = mild disease, 3 = moderate disease, 4 = severe disease and 5 = very severe disease). The sIGA assessed clinical characteristics of erythema, infiltration, papulation, oozing and crusting for the overall severity assessment at the time of evaluation. When the skin condition improves, the change from baseline at each timepoint indicates negative value (i.e. the higher the absolute value is, the more the condition improves).

    Time frame: baseline to Week 12 (Part A)

  6. Changes From Baseline in Static Investigator's Global Assessment (sIGA) (Part A + Part B, ITT Long Population)

    The sIGA consisted of a 6-point severity scale from clear to very severe disease (0 = clear, 1 = almost clear, 2 = mild disease, 3 = moderate disease, 4 = severe disease and 5 = very severe disease). The sIGA assessed clinical characteristics of erythema, infiltration, papulation, oozing and crusting for the overall severity assessment at the time of evaluation. When the skin condition improves, the change from baseline at each timepoint indicates negative value (i.e. the higher the absolute value is, the more the condition improves).

    Time frame: baseline to Week 12 (Part A), up to Week 64 (Part B)

  7. Changes From Baseline in Body Surface Area (BSA) of Atopic Dermatitis (AD) Involvement (Part A, PP Population)

    The total BSA affected by AD was assessed as part of SCORAD. The BSA is a measure of the severity of AD, and it is considered to be severe when the rash with strong inflammation is 10 % or more of the total BSA. When the BSA of AD involvement decreases, the change from baseline at each timepoint indicates negative value (i.e. the higher the absolute value is, the more the BSA of AD involvement decreases).

    Time frame: baseline to Week 12 (Part A)

  8. Changes From Baseline in Body Surface Area (BSA) of Atopic Dermatitis (AD) Involvement (Part A + Part B, ITT Long Population)

    The total BSA affected by AD was assessed as part of SCORAD. The BSA is a measure of the severity of AD, and it is considered to be severe when the rash with strong inflammation is 10 % or more of the total BSA. When the BSA of AD involvement decreases, the change from baseline at each timepoint indicates negative value (i.e. the higher the absolute value is, the more the BSA of AD involvement decreases).

    Time frame: baseline to Week 12 (Part A), up to Week 64 (Part B)

07

Results

Posted Nov 22, 2021

Participant flow

The patients were enrolled at 57 investigational sites in the UK, Germany, Poland, Japan, and the US.

Placebo-controlled (Part A)
Participant flow — Placebo-controlled (Part A)
MilestonePlaceboNemoliozumab (0.1 mg/kg) Q4WNemoliozumab (0.5 mg/kg) Q4WNemoliozumab (2.0 mg/kg) Q4WNemoliozumab (2.0 mg/kg) Q8W
Started5353545252
Completed4444454538
Not completed999714
Withdrew: Adverse event15224
Withdrew: Lack of efficacy31121
Withdrew: Withdrawal by subject52627
Withdrew: Lost to follow-up01010
Withdrew: Others (not classified above reasons)00002
Active-to-active (Part B)
Participant flow — Active-to-active (Part B)
MilestonePlaceboNemoliozumab (0.1 mg/kg) Q4WNemoliozumab (0.5 mg/kg) Q4WNemoliozumab (2.0 mg/kg) Q4WNemoliozumab (2.0 mg/kg) Q8W
Started041383935
Completed031283019
Not completed01010916
Withdrew: Adverse event02013
Withdrew: Lack of efficacy03204
Withdrew: Pregnancy00001
Withdrew: Physician decision00110
Withdrew: Withdrawal by subject04766
Withdrew: Lost to follow-up00001
Withdrew: Others (not classified above reasons)01011
Placebo-to-active (Part B)
Participant flow — Placebo-to-active (Part B)
MilestonePlaceboNemoliozumab (0.1 mg/kg) Q4WNemoliozumab (0.5 mg/kg) Q4WNemoliozumab (2.0 mg/kg) Q4WNemoliozumab (2.0 mg/kg) Q8W
Started01312130
Completed08780
Not completed05550
Withdrew: Adverse event01010
Withdrew: Lack of efficacy00010
Withdrew: Protocol violation00100
Withdrew: Withdrawal by subject03430
Withdrew: Lost to follow-up01000

Outcome measures

PrimaryPercent Changes From Baseline in Pruritus Visual Analogue Scale (VAS) at Week 12

Percent changes from baseline in pruritus VAS at Week 12. VAS indicates pruritus intensity in the last 24 hours, from 0 (no itch) to 10 (worst imaginable itch). When condition of pruritus improves, percent change from baseline at Week 12 indicates negative value (i.e. the higher the absolute value is, the more the condition improves).

Time frame:
baseline to Week 12
Reported as:
Least squares mean · percentage change
Percent Changes From Baseline in Pruritus Visual Analogue Scale (VAS) at Week 12
percentage changePlacebo (Part A)Nemoliozumab (0.1 mg/kg) Q4W (Part A)Nemoliozumab (0.5 mg/kg) Q4W (Part A)Nemoliozumab (2.0 mg/kg) Q4W (Part A)
Percent Changes From Baseline in Pruritus Visual Analogue Scale (VAS) at Week 12-20.07 (-29.94 to -10.21)-41.46 (-51.21 to -31.71)-61.24 (-71.13 to -51.35)-60.46 (-69.98 to -50.95)
Statistical analysis
  • Placebo (Part A) vs Nemoliozumab (0.1 mg/kg) Q4W (Part A) · ANCOVA · p = 0.0027 (Since a hierarchical decision procedure can be regarded as a closed testing procedure, no inflation of the alpha level due to multiple comparisons was necessary, and the global 1-sided significance alpha level of 0.025 was maintained.) · Mean difference (final values): -21.39 · 95% CI -35.25 to -7.53
  • Placebo (Part A) vs Nemoliozumab (0.5 mg/kg) Q4W (Part A) · ANCOVA · p = <0.0001 (Since a hierarchical decision procedure can be regarded as a closed testing procedure, no inflation of the alpha level due to multiple comparisons was necessary, and the global 1-sided significance alpha level of 0.025 was maintained.) · Mean difference (final values): -41.16 · 95% CI -55.17 to -27.15
  • Placebo (Part A) vs Nemoliozumab (2.0 mg/kg) Q4W (Part A) · ANCOVA · p = <0.0001 (Since a hierarchical decision procedure can be regarded as a closed testing procedure, no inflation of the alpha level due to multiple comparisons was necessary, and the global 1-sided significance alpha level of 0.025 was maintained.) · Mean difference (final values): -40.39 · 95% CI -54.11 to -26.67
SecondaryChanges From Baseline in Eczema Area and Severity Index (EASI) (Part A, PP Population)

EASI score was used to measure the severity and extent of atopic eczema. The intensity of a representative area of eczema and the approximate percentage affected by eczema were calculated for each of the four body regions: head and neck, upper limbs, trunk, and lower limbs. The sum of the above 4 body region scores was calculated and should be 0 (none) to 72 (severest). When the condition of eczema improves, the percent change from baseline at each timepoint indicates negative value (i.e. the higher the absolute value is, the more the condition improves).

Time frame:
baseline to Week 12 (Part A)
Reported as:
Mean · percentage change from baseline
Changes From Baseline in Eczema Area and Severity Index (EASI) (Part A, PP Population)
percentage change from baselinePlacebo (Part A)Nemoliozumab (0.1 mg/kg) Q4W (Part A)Nemoliozumab (0.5 mg/kg) Q4W (Part A)Nemoliozumab (2.0 mg/kg) Q4W (Part A)
Week 4-12.12 ± 40.00-26.89 ± 44.48-35.70 ± 44.29-33.86 ± 34.14
Week 8-21.82 ± 47.00-25.17 ± 51.79-46.20 ± 42.62-39.89 ± 34.43
Week 12-20.89 ± 47.63-27.88 ± 50.50-44.57 ± 48.21-40.29 ± 37.70
SecondaryChanges From Baseline in Eczema Area and Severity Index (EASI) (Part A + Part B, ITT Long Population)

EASI score was used to measure the severity and extent of atopic eczema. The intensity of a representative area of eczema and the approximate percentage affected by eczema were calculated for each of the four body regions: head and neck, upper limbs, trunk, and lower limbs. The sum of the above 4 body region scores was calculated and should be 0 (none) to 72 (severest). When the condition of eczema improves, the percent change from baseline at each timepoint indicates negative value (i.e. the higher the absolute value is, the more the condition improves).

Time frame:
baseline to Week 12 (Part A), up to Week 64 (Part B)
Reported as:
Mean · percentage change from baseline
Changes From Baseline in Eczema Area and Severity Index (EASI) (Part A + Part B, ITT Long Population)
percentage change from baselineNemoliozumab (0.1 mg/kg) Q4W (Part A + Part B)Nemoliozumab (0.5 mg/kg) Q4W (Part A + Part B)Nemoliozumab (2.0 mg/kg) Q4W (Part A + Part B)Nemoliozumab (2.0 mg/kg) Q8W (Part A + Part B)
Week 4-25.47 ± 42.41-32.11 ± 43.70-32.48 ± 34.02-25.43 ± 35.58
Week 8-25.13 ± 49.82-47.86 ± 41.38-41.02 ± 36.50-33.35 ± 38.00
Week 12-35.11 ± 47.92-47.75 ± 45.41-46.78 ± 35.15-42.12 ± 40.82
Week 24-55.83 ± 42.25-62.71 ± 44.37-56.26 ± 34.68-51.01 ± 37.07
Week 48-69.90 ± 28.17-71.16 ± 43.31-61.14 ± 44.43-74.29 ± 33.97
Week 60-63.11 ± 41.89-78.81 ± 28.82-70.85 ± 36.24-70.87 ± 32.84
Week 64-68.45 ± 41.62-75.79 ± 25.40-78.91 ± 24.34-69.25 ± 43.96
SecondaryChanges From Baseline in SCORing Atopic Dermatitis (SCORAD) (Part A, PP Population)

SCORAD is a clinical tool used to assess the extent and severity of eczema. Area and intensity, were assessed by the Investigator and subjective symptoms were reported by the patient in order to determine an overall score. The score should be 0 to 103: mild \[\<25\], moderate \[25-50\] or severe \[\>50\]). When the condition of eczema improves, the percent change from baseline at each timepoint indicates negative value (i.e. the higher the absolute value is, the more the condition improves).

Time frame:
baseline to Week 12 (Part A)
Reported as:
Mean · percentage change from baseline
Changes From Baseline in SCORing Atopic Dermatitis (SCORAD) (Part A, PP Population)
percentage change from baselinePlacebo (Part A)Nemoliozumab (0.1 mg/kg) Q4W (Part A)Nemoliozumab (0.5 mg/kg) Q4W (Part A)Nemoliozumab (2.0 mg/kg) Q4W (Part A)
Week 4-6.83 ± 25.97-29.31 ± 23.58-34.59 ± 29.36-29.82 ± 21.65
Week 8-17.29 ± 30.74-26.41 ± 26.60-36.81 ± 29.04-34.72 ± 24.33
Week 12-15.97 ± 26.99-27.22 ± 25.81-39.49 ± 32.68-38.31 ± 28.85
SecondaryChanges From Baseline in SCORing Atopic Dermatitis (SCORAD) (Part A + Part B, ITT Long Population)

SCORAD is a clinical tool used to assess the extent and severity of eczema. Area and intensity, were assessed by the Investigator and subjective symptoms were reported by the patient in order to determine an overall score. The score should be 0 to 103: mild \[\<25\], moderate \[25-50\] or severe \[\>50\]). When the condition of eczema improves, the percent change from baseline at each timepoint indicates negative value (i.e. the higher the absolute value is, the more the condition improves).

Time frame:
baseline to Week 12 (Part A), up to Week 64 (Part B)
Reported as:
Mean · percentage change from baseline
Changes From Baseline in SCORing Atopic Dermatitis (SCORAD) (Part A + Part B, ITT Long Population)
percentage change from baselineNemoliozumab (0.1 mg/kg) Q4W (Part A + Part B)Nemoliozumab (0.5 mg/kg) Q4W (Part A + Part B)Nemoliozumab (2.0 mg/kg) Q4W (Part A + Part B)Nemoliozumab (2.0 mg/kg) Q8W (Part A + Part B)
Week 4-27.73 ± 23.92-30.30 ± 30.39-28.20 ± 22.65-25.31 ± 22.68
Week 8-29.05 ± 27.17-36.16 ± 28.60-37.52 ± 23.34-31.81 ± 28.42
Week 12-36.35 ± 22.24-42.22 ± 30.72-42.60 ± 27.12-41.85 ± 20.79
Week 24-48.73 ± 27.64-58.15 ± 28.15-52.00 ± 24.97-49.97 ± 24.99
Week 48-55.82 ± 24.21-59.20 ± 28.61-53.82 ± 29.98-66.15 ± 24.43
Week 60-55.08 ± 24.22-64.02 ± 24.24-63.26 ± 25.04-61.03 ± 24.27
Week 64-56.55 ± 28.25-64.02 ± 27.72-66.61 ± 19.90-63.07 ± 27.96
SecondaryChanges From Baseline in Static Investigator's Global Assessment (sIGA) (Part A, PP Population)

The sIGA consisted of a 6-point severity scale from clear to very severe disease (0 = clear, 1 = almost clear, 2 = mild disease, 3 = moderate disease, 4 = severe disease and 5 = very severe disease). The sIGA assessed clinical characteristics of erythema, infiltration, papulation, oozing and crusting for the overall severity assessment at the time of evaluation. When the skin condition improves, the change from baseline at each timepoint indicates negative value (i.e. the higher the absolute value is, the more the condition improves).

Time frame:
baseline to Week 12 (Part A)
Reported as:
Mean · change from baseline
Changes From Baseline in Static Investigator's Global Assessment (sIGA) (Part A, PP Population)
change from baselinePlacebo (Part A)Nemoliozumab (0.1 mg/kg) Q4W (Part A)Nemoliozumab (0.5 mg/kg) Q4W (Part A)Nemoliozumab (2.0 mg/kg) Q4W (Part A)
Week 4-0.2 ± 0.8-0.8 ± 0.9-0.9 ± 0.9-0.6 ± 0.9
Week 8-0.5 ± 1.2-0.7 ± 1.0-1.0 ± 1.2-0.8 ± 1.0
Week 12-0.3 ± 1.0-0.7 ± 1.0-1.0 ± 1.1-0.8 ± 1.1
SecondaryChanges From Baseline in Static Investigator's Global Assessment (sIGA) (Part A + Part B, ITT Long Population)

The sIGA consisted of a 6-point severity scale from clear to very severe disease (0 = clear, 1 = almost clear, 2 = mild disease, 3 = moderate disease, 4 = severe disease and 5 = very severe disease). The sIGA assessed clinical characteristics of erythema, infiltration, papulation, oozing and crusting for the overall severity assessment at the time of evaluation. When the skin condition improves, the change from baseline at each timepoint indicates negative value (i.e. the higher the absolute value is, the more the condition improves).

Time frame:
baseline to Week 12 (Part A), up to Week 64 (Part B)
Reported as:
Mean · change from baseline
Changes From Baseline in Static Investigator's Global Assessment (sIGA) (Part A + Part B, ITT Long Population)
change from baselineNemoliozumab (0.1 mg/kg) Q4W (Part A + Part B)Nemoliozumab (0.5 mg/kg) Q4W (Part A + Part B)Nemoliozumab (2.0 mg/kg) Q4W (Part A + Part B)Nemoliozumab (2.0 mg/kg) Q8W (Part A + Part B)
Week 4-0.7 ± 0.9-0.8 ± 0.9-0.6 ± 0.9-0.4 ± 0.8
Week 8-0.8 ± 1.0-1.0 ± 1.2-0.9 ± 0.9-0.5 ± 0.9
Week 12-0.9 ± 0.9-1.1 ± 1.1-0.9 ± 1.0-0.9 ± 0.8
Week 24-1.5 ± 1.1-1.7 ± 1.0-1.2 ± 1.0-1.2 ± 1.1
Week 48-1.7 ± 1.2-1.8 ± 0.8-1.4 ± 1.2-2.0 ± 1.2
Week 60-1.9 ± 1.0-2.0 ± 0.9-1.7 ± 1.1-1.7 ± 1.1
Week 64-1.9 ± 1.1-1.9 ± 0.9-1.7 ± 1.0-1.8 ± 1.3
SecondaryChanges From Baseline in Body Surface Area (BSA) of Atopic Dermatitis (AD) Involvement (Part A, PP Population)

The total BSA affected by AD was assessed as part of SCORAD. The BSA is a measure of the severity of AD, and it is considered to be severe when the rash with strong inflammation is 10 % or more of the total BSA. When the BSA of AD involvement decreases, the change from baseline at each timepoint indicates negative value (i.e. the higher the absolute value is, the more the BSA of AD involvement decreases).

Time frame:
baseline to Week 12 (Part A)
Reported as:
Mean · percentage change from baseline
Changes From Baseline in Body Surface Area (BSA) of Atopic Dermatitis (AD) Involvement (Part A, PP Population)
percentage change from baselinePlacebo (Part A)Nemoliozumab (0.1 mg/kg) Q4W (Part A)Nemoliozumab (0.5 mg/kg) Q4W (Part A)Nemoliozumab (2.0 mg/kg) Q4W (Part A)
Week 4-7.48 ± 37.14-12.11 ± 43.69-23.49 ± 40.93-18.44 ± 35.47
Week 8-14.44 ± 49.29-14.90 ± 45.84-27.23 ± 47.17-22.99 ± 38.58
Week 12-13.29 ± 49.87-17.54 ± 47.16-19.68 ± 67.49-24.36 ± 41.84
SecondaryChanges From Baseline in Body Surface Area (BSA) of Atopic Dermatitis (AD) Involvement (Part A + Part B, ITT Long Population)

The total BSA affected by AD was assessed as part of SCORAD. The BSA is a measure of the severity of AD, and it is considered to be severe when the rash with strong inflammation is 10 % or more of the total BSA. When the BSA of AD involvement decreases, the change from baseline at each timepoint indicates negative value (i.e. the higher the absolute value is, the more the BSA of AD involvement decreases).

Time frame:
baseline to Week 12 (Part A), up to Week 64 (Part B)
Reported as:
Mean · percentage change from baseline
Changes From Baseline in Body Surface Area (BSA) of Atopic Dermatitis (AD) Involvement (Part A + Part B, ITT Long Population)
percentage change from baselineNemoliozumab (0.1 mg/kg) Q4W (Part A + Part B)Nemoliozumab (0.5 mg/kg) Q4W (Part A + Part B)Nemoliozumab (2.0 mg/kg) Q4W (Part A + Part B)Nemoliozumab (2.0 mg/kg) Q8W (Part A + Part B)
Week 4-10.12 ± 45.56-23.28 ± 38.96-17.98 ± 35.12-2.79 ± 54.12
Week 8-18.08 ± 45.82-29.58 ± 47.13-24.64 ± 37.49-6.66 ± 59.40
Week 12-24.53 ± 49.77-25.31 ± 63.43-25.91 ± 44.40-18.56 ± 52.30
Week 24-48.13 ± 39.07-51.41 ± 44.10-40.53 ± 42.94-36.91 ± 40.99
Week 48-65.21 ± 32.63-69.20 ± 39.95-49.66 ± 44.18-59.97 ± 50.32
Week 60-60.41 ± 37.00-70.44 ± 35.81-60.99 ± 48.00-58.38 ± 44.97
Week 64-62.54 ± 40.92-66.01 ± 36.38-63.35 ± 40.37-60.54 ± 55.96

Adverse events

Collected over baseline to Week 12 (Part A), up to Week 64 (Part B), Safety Follow-up period. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo (Part A)0/53 (0%)1/53 (1.9%)27/53 (50.9%)
Nemoliozumab (0.1 mg/kg) Q4W (Part A)0/53 (0%)1/53 (1.9%)29/53 (54.7%)
Nemoliozumab (0.5 mg/kg) Q4W (Part A)0/54 (0%)0/54 (0%)23/54 (42.6%)
Nemoliozumab (2.0 mg/kg) Q4W (Part A)0/52 (0%)3/52 (5.8%)27/52 (51.9%)
Nemoliozumab (2.0 mg/kg) Q8W (Part A)0/52 (0%)5/52 (9.6%)25/52 (48.1%)
Nemoliozumab (0.1 mg/kg) Q4W (Part A + Part B)0/53 (0%)3/53 (5.7%)37/53 (69.8%)
Nemoliozumab (0.5 mg/kg) Q4W (Part A + Part B)0/54 (0%)3/54 (5.6%)35/54 (64.8%)
Nemoliozumab (2.0 mg/kg) Q4W (Part A + Part B)0/52 (0%)4/52 (7.7%)33/52 (63.5%)
Nemoliozumab (2.0 mg/kg) Q8W (Part A + Part B)0/52 (0%)9/52 (17.3%)35/52 (67.3%)
Most frequent serious events
Showing 10 of 20
Most frequent serious events
EventPlacebo (Part A)Nemoliozumab (0.1 mg/kg) Q4W (Part A)Nemoliozumab (0.5 mg/kg) Q4W (Part A)Nemoliozumab (2.0 mg/kg) Q4W (Part A)Nemoliozumab (2.0 mg/kg) Q8W (Part A)Nemoliozumab (0.1 mg/kg) Q4W (Part A + Part B)Nemoliozumab (0.5 mg/kg) Q4W (Part A + Part B)Nemoliozumab (2.0 mg/kg) Q4W (Part A + Part B)Nemoliozumab (2.0 mg/kg) Q8W (Part A + Part B)
Dermatitis atopicSkin and subcutaneous tissue disorders0/530/530/542/521/520/531/542/522/52
InfectionInfections and infestations0/530/530/540/522/520/530/540/522/52
Dermatitis exfoliativeSkin and subcutaneous tissue disorders0/530/530/540/521/520/530/540/521/52
Herpes simplexInfections and infestations0/530/530/540/521/520/530/540/521/52
Herpes zosterInfections and infestations0/530/530/540/521/520/530/540/521/52
PyelonephritisInfections and infestations0/530/530/540/520/520/530/540/521/52
Skin infectionInfections and infestations0/530/530/541/520/520/530/541/520/52
Coronary artery stenosisCardiac disorders0/530/530/540/520/520/530/540/521/52
Grand mal convulsionNervous system disorders0/530/530/540/520/520/530/540/521/52
Parkinson's diseaseNervous system disorders0/530/530/540/521/520/530/540/521/52
Most frequent other events
Showing 10 of 19
Most frequent other events
EventPlacebo (Part A)Nemoliozumab (0.1 mg/kg) Q4W (Part A)Nemoliozumab (0.5 mg/kg) Q4W (Part A)Nemoliozumab (2.0 mg/kg) Q4W (Part A)Nemoliozumab (2.0 mg/kg) Q8W (Part A)Nemoliozumab (0.1 mg/kg) Q4W (Part A + Part B)Nemoliozumab (0.5 mg/kg) Q4W (Part A + Part B)Nemoliozumab (2.0 mg/kg) Q4W (Part A + Part B)Nemoliozumab (2.0 mg/kg) Q8W (Part A + Part B)
NasopharyngitisInfections and infestations8/539/536/545/527/5215/5314/5415/5212/52
Dermatitis atopicSkin and subcutaneous tissue disorders7/5311/5310/549/529/5215/5312/5412/529/52
Blood creatine phosphokinase increasedInvestigations3/532/532/544/523/525/533/549/526/52
Oedema peripheralGeneral disorders0/532/533/545/522/522/533/546/522/52
Upper respiratory tract infectionInfections and infestations6/534/531/544/525/526/533/545/525/52
ImpetigoInfections and infestations0/534/530/540/520/526/533/540/523/52
HeadacheNervous system disorders0/533/532/543/521/523/536/545/522/52
InfluenzaInfections and infestations0/530/530/540/520/525/531/542/520/52
PharyngitisInfections and infestations0/530/530/540/520/521/533/543/521/52
FolliculitisInfections and infestations3/530/530/540/521/521/530/541/523/52

Baseline characteristics

The per-protocol (PP) population in Part A was used for the analysis. The PP population was defined as a subset of the intent to treat (ITT) population excluding some of the major protocol violators, patients who were withdrawn before being evaluated for pruritus Visual Analogue Scale (VAS) at Week 8, or those who withdrew prior to receiving two or more study drug administrations. Patients who received the wrong study drug were also excluded from the PP population.

Age, Continuous
Age, Continuous(years)Placebo (Part A)Nemoliozumab (0.1 mg/kg) Q4W (Part A)Nemoliozumab (0.5 mg/kg) Q4W (Part A)Nemoliozumab (2.0 mg/kg) Q4W (Part A)Nemoliozumab (2.0 mg/kg) Q8W (Part A)Total
Mean35.7 ± 13.333.9 ± 10.233.0 ± 11.533.7 ± 12.234.6 ± 13.334.2 ± 12.1
Age, Customized
Age, Customized(Participants)Placebo (Part A)Nemoliozumab (0.1 mg/kg) Q4W (Part A)Nemoliozumab (0.5 mg/kg) Q4W (Part A)Nemoliozumab (2.0 mg/kg) Q4W (Part A)Nemoliozumab (2.0 mg/kg) Q8W (Part A)Total
Age Category — < 20 years403119
Age Category — 20 -< 30 years142122202198
Age Category — 30 -< 40 years1015713752
Age Category — 40 -< 50 years8467732
Age Category — 50 -< 60 years8674732
Age Category — > 60 years200226
Sex: Female, Male
Sex: Female, Male(Participants)Placebo (Part A)Nemoliozumab (0.1 mg/kg) Q4W (Part A)Nemoliozumab (0.5 mg/kg) Q4W (Part A)Nemoliozumab (2.0 mg/kg) Q4W (Part A)Nemoliozumab (2.0 mg/kg) Q8W (Part A)Total
Female2321271821110
Male2325182924119
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Placebo (Part A)Nemoliozumab (0.1 mg/kg) Q4W (Part A)Nemoliozumab (0.5 mg/kg) Q4W (Part A)Nemoliozumab (2.0 mg/kg) Q4W (Part A)Nemoliozumab (2.0 mg/kg) Q8W (Part A)Total
Hispanic or Latino010113
Not Hispanic or Latino4545444544223
Unknown or Not Reported101103
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Placebo (Part A)Nemoliozumab (0.1 mg/kg) Q4W (Part A)Nemoliozumab (0.5 mg/kg) Q4W (Part A)Nemoliozumab (2.0 mg/kg) Q4W (Part A)Nemoliozumab (2.0 mg/kg) Q8W (Part A)Total
American Indian or Alaska Native000101
Asian131711151470
Native Hawaiian or Other Pacific Islander000000
Black or African American1361415
White3226273027142
More than one race000000
Unknown or Not Reported001001
Height
Height(Centimetre)Placebo (Part A)Nemoliozumab (0.1 mg/kg) Q4W (Part A)Nemoliozumab (0.5 mg/kg) Q4W (Part A)Nemoliozumab (2.0 mg/kg) Q4W (Part A)Nemoliozumab (2.0 mg/kg) Q8W (Part A)Total
Mean167.81 ± 8.84170.19 ± 10.52167.41 ± 9.44170.04 ± 8.84167.58 ± 9.63168.62 ± 9.47
Weight
Weight(Kilogram)Placebo (Part A)Nemoliozumab (0.1 mg/kg) Q4W (Part A)Nemoliozumab (0.5 mg/kg) Q4W (Part A)Nemoliozumab (2.0 mg/kg) Q4W (Part A)Nemoliozumab (2.0 mg/kg) Q8W (Part A)Total
Mean74.20 ± 21.6076.01 ± 22.9073.40 ± 19.9872.51 ± 16.0472.63 ± 20.9673.75 ± 20.27
Weight Category
Weight Category(Participants)Placebo (Part A)Nemoliozumab (0.1 mg/kg) Q4W (Part A)Nemoliozumab (0.5 mg/kg) Q4W (Part A)Nemoliozumab (2.0 mg/kg) Q4W (Part A)Nemoliozumab (2.0 mg/kg) Q8W (Part A)Total
< 60 kg111215111564
>- 60 kg3534303630165

2 further baseline measures are reported on the registry.

08

Study locations

18 sites
  • Anniston, Alabama 36207, United States
  • San Diego, California 92122, United States
  • Miami, Florida 33142, United States
  • Alpharetta, Georgia 30022, United States
  • Arlington Heights, Illinois 60005, United States
  • Chicago, Illinois 60612, United States
  • Indianapolis, Indiana 46256, United States
  • Louisville, Kentucky 40202, United States
  • Louisville, Kentucky 40217, United States
  • Bay City, Michigan 48706, United States
  • New York, New York 10016, United States
  • Charlotte, North Carolina 28226, United States
  • Cleveland, Ohio 44106, United States
  • Portland, Oregon 97239, United States
  • Charleston, South Carolina 29407, United States
  • Charleston, South Carolina 29425, United States
  • College Station, Texas 77845, United States
  • Norfolk, Virginia 23507, United States
09

References and documents

Publications

  • Kabashima K, Furue M, Hanifin JM, Pulka G, Wollenberg A, Galus R, Etoh T, Mihara R, Nakano M, Ruzicka T. Nemolizumab in patients with moderate-to-severe atopic dermatitis: Randomized, phase II, long-term extension study. J Allergy Clin Immunol. 2018 Oct;142(4):1121-1130.e7. doi: 10.1016/j.jaci.2018.03.018. Epub 2018 May 10. PubMed 29753033 ↗
  • Ruzicka T, Hanifin JM, Furue M, Pulka G, Mlynarczyk I, Wollenberg A, Galus R, Etoh T, Mihara R, Yoshida H, Stewart J, Kabashima K; XCIMA Study Group. Anti-Interleukin-31 Receptor A Antibody for Atopic Dermatitis. N Engl J Med. 2017 Mar 2;376(9):826-835. doi: 10.1056/NEJMoa1606490. PubMed 28249150 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2013, a primary completion of Apr 2015 and a completion of Jun 2016. It does not say whether these dates are actual or estimated.

Results were first posted in Nov 2021, 6 years 7 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 31, 2013
First posted
Nov 19, 2013
Start
Nov 2013
Primary completionActual
Apr 2015
CompletionActual
Jun 2016
Results first posted
Nov 22, 2021
Last update
Jan 25, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 25, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01986933
Responsible party
Sponsor
First posted
Nov 19, 2013
Start date
Nov 2013
Primary completion
Apr 2015
Completion
Jun 2016
Results posted
Nov 22, 2021
Last update
Jan 25, 2022

Study contacts

Ryosuke Mihara
study director · Chugai Pharmaceutical

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Nemolizumab

Start the discussion